CN101889079B - 适于临床应用的人胎盘间质细胞库的建立方法 - Google Patents
适于临床应用的人胎盘间质细胞库的建立方法 Download PDFInfo
- Publication number
- CN101889079B CN101889079B CN2008801154315A CN200880115431A CN101889079B CN 101889079 B CN101889079 B CN 101889079B CN 2008801154315 A CN2008801154315 A CN 2008801154315A CN 200880115431 A CN200880115431 A CN 200880115431A CN 101889079 B CN101889079 B CN 101889079B
- Authority
- CN
- China
- Prior art keywords
- cell
- placenta
- serum
- donor
- blood serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 131
- 230000003169 placental effect Effects 0.000 title abstract description 8
- 210000002826 placenta Anatomy 0.000 claims abstract description 146
- 210000002966 serum Anatomy 0.000 claims abstract description 113
- 210000004700 fetal blood Anatomy 0.000 claims abstract description 64
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 32
- 230000000392 somatic effect Effects 0.000 claims description 31
- 210000001113 umbilicus Anatomy 0.000 claims description 31
- 235000015097 nutrients Nutrition 0.000 claims description 25
- 238000003860 storage Methods 0.000 claims description 25
- 210000005059 placental tissue Anatomy 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- 210000001691 amnion Anatomy 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000012546 transfer Methods 0.000 claims description 13
- 210000001136 chorion Anatomy 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 230000002785 anti-thrombosis Effects 0.000 claims description 8
- 229960004676 antithrombotic agent Drugs 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 210000003954 umbilical cord Anatomy 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000005057 refrigeration Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 210000003462 vein Anatomy 0.000 claims description 5
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 238000004590 computer program Methods 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 227
- 239000000243 solution Substances 0.000 description 36
- 210000000130 stem cell Anatomy 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000012258 culturing Methods 0.000 description 11
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 244000309466 calf Species 0.000 description 8
- 210000004252 chorionic villi Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000002706 plastid Anatomy 0.000 description 7
- 102000029816 Collagenase Human genes 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- 210000003995 blood forming stem cell Anatomy 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108010007093 dispase Proteins 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003425 amniotic epithelial cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical class [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035771 neuroregeneration Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Description
成分(mg/L) | MD200 | MD201 | MD202 | MD203 | MD204 |
氯化钙 | 200 | 200 | 200 | 200 | 200 |
九水硝酸铁 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
氯化钾 | 400 | 400 | 400 | 400 | 400 |
无水硫酸镁 | 97.67 | 97.67 | 97.67 | 97.67 | 97.67 |
氯化钠 | 6400 | 6400 | 6400 | 6400 | 4400 |
无水磷酸二氢钠 | 108.7 | 108.7 | 108.7 | 108.7 | 108.7 |
L-精氨酸盐酸盐 | 84 | 84 | 84 | 84 | 84 |
L-胱氨酸盐酸盐 | 63 | 63 | 63 | 63 | 63 |
L-谷氨酰胺 | 584 | 584 | 584 | 584 | 584 |
甘氨酸 | 30 | 30 | 30 | 30 | 30 |
L-组氨酸盐酸盐 | 42 | 42 | 42 | 42 | 42 |
L-异亮氨酸 | 105 | 105 | 105 | 105 | 105 |
L-亮氨酸 | 105 | 105 | 105 | 105 | 105 |
L-赖氨酸盐酸盐 | 146 | 146 | 146 | 146 | 146 |
L-蛋氨酸 | 30 | 30 | 30 | 30 | 30 |
L-苯丙氨酸 | 66 | 66 | 66 | 66 | 66 |
L-丝氨酸 | 42 | 42 | 42 | 42 | 42 |
L-苏氨酸 | 95 | 95 | 95 | 95 | 95 |
L-色氨酸 | 16 | 16 | 16 | 16 | 16 |
L-酪氨酸 | 72 | 72 | 72 | 72 | 72 |
L-缬氨酸 | 94 | 94 | 94 | 94 | 94 |
D-葡萄糖 | 1000 | 4500 | 4500 | 4500 | 4500 |
酚红 | 15 | 15 | 15 | - | 15 |
丙酮酸钠 | 110 | - | 110 | - | - |
HEPES | - | - | - | - | 5958 |
D-泛酸钙 | 4 | 4 | 4 | 4 | 4 |
氯化胆碱 | 4 | 4 | 4 | 4 | 4 |
叶酸 | 4 | 4 | 4 | 4 | 4 |
i-肌醇 | 7.2 | 7.2 | 7.2 | 7.2 | 7.2 |
烟酰胺 | 4 | 4 | 4 | 4 | 4 |
盐酸吡哆醛 | 4 | 4 | 4 | 4 | 4 |
核黄素 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
盐酸硫胺 | 4 | 4 | 4 | 4 | 4 |
pH(无碳酸氢钠) | 6.3±0.3 | 6.3±0.3 | 6.3±0.3 | 6.3±0.3 | 5.7±0.3 |
使用血清 | 细胞培养期间 | 细胞分裂周期 |
胎牛血清 | 第2-6代 | 24-30小时 |
自体人脐带血血清 | 第2-6代 | 24-30小时 |
非自体人脐带血血清 | 第2-4代 | 24-36小时 |
Claims (10)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2008/001756 WO2010043076A1 (zh) | 2008-10-17 | 2008-10-17 | 适于临床应用的人胎盘间质细胞库的建立方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101889079A CN101889079A (zh) | 2010-11-17 |
CN101889079B true CN101889079B (zh) | 2012-08-08 |
Family
ID=42106193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801154315A Expired - Fee Related CN101889079B (zh) | 2008-10-17 | 2008-10-17 | 适于临床应用的人胎盘间质细胞库的建立方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100272694A1 (zh) |
EP (1) | EP2248887A4 (zh) |
CN (1) | CN101889079B (zh) |
WO (1) | WO2010043076A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105765059A (zh) * | 2013-11-04 | 2016-07-13 | 伊索波根控股公司 | 细胞培养方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
JP6741597B2 (ja) * | 2014-07-08 | 2020-08-19 | ラ ジョンチャンRA, Jeong Chan | 幹細胞の安定性増進用組成物 |
CA2986702C (en) | 2015-05-21 | 2023-04-04 | David Wang | Modified demineralized cortical bone fibers |
US10373109B2 (en) | 2016-08-04 | 2019-08-06 | Fanuc Corporation | System and method for iPS cell bank using media |
US11259520B2 (en) * | 2016-08-04 | 2022-03-01 | Fanuc Corporation | Stem cell manufacturing system, stem cell information management system, cell transport apparatus, and stem cell frozen storage apparatus |
US10354218B2 (en) | 2016-08-04 | 2019-07-16 | Fanuc Corporation | System and method for iPS cell bank using internet technology |
CN110903952B (zh) * | 2019-11-06 | 2023-05-26 | 天晴干细胞股份有限公司 | 一种利用保护液及胎盘挤压器分离提纯胎盘血及复苏的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1810959A (zh) * | 2006-01-13 | 2006-08-02 | 深圳市北科生物科技有限公司 | 人羊膜间充质干细胞的分离及培养方法及医用组合物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4411594C1 (de) * | 1994-03-30 | 1995-12-14 | Deutsches Rheumaforschungszent | Testkit zur Bestimmung von Histokompatibilitäts-Antigenen |
US6582953B2 (en) * | 1999-04-14 | 2003-06-24 | Breonics, Inc. | Organ chamber for exsanguinous metabolic support system |
NZ568250A (en) * | 2001-01-02 | 2009-07-31 | Stemron Inc | A method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same |
EP2336300B1 (en) * | 2001-02-14 | 2015-07-08 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP1367892B1 (en) * | 2001-02-14 | 2013-10-30 | Anthrogenesis Corporation | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
US20030039952A1 (en) * | 2001-08-21 | 2003-02-27 | Gamida-Cell Ltd. | Method of preparing and thawing cryopreserved cells |
CN1195055C (zh) * | 2001-09-06 | 2005-03-30 | 周胜利 | 从胎盘组织中提取造血干细胞用于建立造血干细胞库的新方法 |
US7060494B2 (en) * | 2002-04-09 | 2006-06-13 | Reliance Life Sciences Pvt. Ltd. | Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof |
US20040161419A1 (en) * | 2002-04-19 | 2004-08-19 | Strom Stephen C. | Placental stem cells and uses thereof |
ZA200404101B (en) * | 2003-05-26 | 2005-03-07 | Reliance Life Sciences Pvt Ltd | In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use. |
US20070178591A1 (en) * | 2004-06-25 | 2007-08-02 | Renomedix Institute, Inc | Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient |
US20050186672A1 (en) * | 2004-01-27 | 2005-08-25 | Reliance Life Sciences Pvt. Ltd. | Tissue system with undifferentiated stem cells derived from corneal limbus |
AU2005231680A1 (en) * | 2004-03-26 | 2005-10-20 | Celgene Corporation | Systems and methods for providing a stem cell bank |
RU2252252C1 (ru) * | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Способ выделения мезенхимальных стволовых клеток |
GB2432166B (en) * | 2004-08-16 | 2008-01-02 | Cellres Corp Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
EP1859024A2 (en) * | 2005-01-27 | 2007-11-28 | Regenetech, Inc. | Method of providing readily available cellular material derived from cord blood, and a composition thereof |
US20060182724A1 (en) * | 2005-02-15 | 2006-08-17 | Riordan Neil H | Method for expansion of stem cells |
CA2629283A1 (en) * | 2005-11-14 | 2007-05-24 | The New England Medical Center Hospitals, Inc. | Methods for preparing cord matrix stem cells (cmsc) for long term storage and for preparing a segment of umbilical cord for cryopreservation |
KR20180105266A (ko) * | 2005-12-29 | 2018-09-27 | 안트로제네시스 코포레이션 | 태반 줄기 세포 집단 |
KR100908481B1 (ko) * | 2006-04-24 | 2009-07-21 | 코아스템(주) | 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법 |
-
2008
- 2008-10-17 US US12/747,307 patent/US20100272694A1/en not_active Abandoned
- 2008-10-17 CN CN2008801154315A patent/CN101889079B/zh not_active Expired - Fee Related
- 2008-10-17 WO PCT/CN2008/001756 patent/WO2010043076A1/zh active Application Filing
- 2008-10-17 EP EP08877353.6A patent/EP2248887A4/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1810959A (zh) * | 2006-01-13 | 2006-08-02 | 深圳市北科生物科技有限公司 | 人羊膜间充质干细胞的分离及培养方法及医用组合物 |
Non-Patent Citations (2)
Title |
---|
Maddalena Soncini.Isolation and characterization of mesenchymal cells from human fetal membranes.《Journal of Tissue Engineering and Regenerative Medicine》.2007,第1卷(第4期),第299页第3.1节. * |
旷文勇.脐带血血清培养体系扩增人骨髓间充质干细胞及其生物学特征.《中国组织工程研究与临床康复》.2008,第12卷(第21期),第4045页右栏第2段. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105765059A (zh) * | 2013-11-04 | 2016-07-13 | 伊索波根控股公司 | 细胞培养方法 |
CN105765059B (zh) * | 2013-11-04 | 2021-05-25 | 伊索波根控股公司 | 细胞培养方法 |
Also Published As
Publication number | Publication date |
---|---|
US20100272694A1 (en) | 2010-10-28 |
CN101889079A (zh) | 2010-11-17 |
EP2248887A1 (en) | 2010-11-10 |
EP2248887A4 (en) | 2013-04-17 |
WO2010043076A1 (zh) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101889079B (zh) | 适于临床应用的人胎盘间质细胞库的建立方法 | |
US11821006B2 (en) | Method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord | |
US20080064098A1 (en) | Procurement, isolation and cryopreservation of maternal placental cells | |
CN103074298B (zh) | 一种人脂肪间充质干细胞库及其构建方法 | |
CN101629165B (zh) | 一种原始间充质干细胞的制备方法 | |
CN103667187A (zh) | 一种人脂肪干细胞的分离培养方法和干细胞库的构建方法 | |
CN104560870A (zh) | 一种制备蜕膜间充质干细胞的方法 | |
CN105420179A (zh) | 一种从脐带和胎盘羊膜组织同时提取上皮细胞和间充质干细胞的方法 | |
CN102433301A (zh) | 一种提取扩增单克隆间充质干细胞的方法及所用培养液 | |
CN102712905A (zh) | 从脐带组织分离包括间充质祖细胞亚群的单核细胞和包括内皮祖细胞亚群的血管细胞的方法 | |
CN107385517A (zh) | 间充质干细胞库的构建方法 | |
CN104560869A (zh) | 一种制备绒毛膜间充质干细胞的方法 | |
CN110317781B (zh) | 间充质干细胞冻存和复苏的方法 | |
CN110317782B (zh) | 提高间充质干细胞复苏后存活的方法和所用的冻存液 | |
KR20210045443A (ko) | 아카보즈 또는 스타키오스를 포함하는 포유동물 세포 보존용 액 | |
CN106190979A (zh) | 体外培养造血干/前驱细胞的方法及其组成物 | |
WO2022056991A1 (zh) | 脐带来源的间充质干细胞及其制备方法和应用 | |
US20210087532A1 (en) | Compositions and method for establishing organoid cultures from cryogenically preserved tissue | |
CN103160459B (zh) | 一种优秀冰雪运动员胎盘干细胞分离培养及鉴定方法 | |
RU2783992C2 (ru) | Способ выделения мезенхимальных стволовых клеток из амниотической мембраны пуповины с применением клеточной культуральной среды | |
TWI836505B (zh) | 從臍帶的羊膜分離間質幹細胞的方法、從臍帶的羊膜分離的間質幹細胞群以及用於從臍帶的羊膜分離間質幹細胞的細胞培養基 | |
LOKANATHAN | The Optimal Cryo Revival Period of Cryopreserved Wharton’s Jelly Derived-Mesenchymal Stem Cells | |
CN111304158A (zh) | 辛酰化Ghrelin在促进牛卵母细胞卵丘细胞复合体雌二醇和孕酮分泌中的应用 | |
Frolova et al. | Preparation of a Single-Cell Suspension from Tumor Biopsy Samples for Single-Cell RNA Sequencing | |
CN104818246A (zh) | 一种兔脂肪干细胞的分离培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING YALIAN BAIDE TECHNOLOGY + TRADE CO., LTD. Free format text: FORMER OWNER: AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY Effective date: 20131223 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 750000 YINCHUAN, NINGXIA HUI AUTONOMOUS REGION TO: 102629 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131223 Address after: 102629 Beijing Huang Cun town, Beijing biological engineering and pharmaceutical industry base, Tianhe West Road, No. 19, Daxing District Patentee after: Beijing Lian Lian Black & Decker Technology & Trade Co.,Ltd. Address before: 750000 No. 804 Shengli Street, Xingqing District, the Ningxia Hui Autonomous Region, Yinchuan Patentee before: Affiliated Hospital of Ningxia Medical University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120808 |
|
CF01 | Termination of patent right due to non-payment of annual fee |